Ensartinib in Resected ALK-Positive Non-Small-Cell Lung Cancer
Clinical Snapshot
PICO Framework
| P — Population | Adults with completely resected, ALK-positive stage IB to IIIB non-small-cell lung cancer (NSCLC) who had completed adjuvant platinum-based chemotherapy |
| I — Intervention | Ensartinib 225 mg orally once daily for 24 months (second-generation ALK inhibitor) |
| C — Comparator | Matched placebo orally once daily for 24 months |
| O — Outcomes | Primary: disease-free survival (DFS) in patients with stage II–IIIB NSCLC; Key secondary: DFS in the overall population (stage IB–IIIB); Additional secondary: overall survival (OS), safety and tolerability |
Bottom Line
The ELEVATE trial demonstrates a striking disease-free survival benefit with adjuvant ensartinib in completely resected, ALK-positive stage IB–IIIB NSCLC following chemotherapy. The hazard ratio of 0.20 — representing an 80% relative reduction in recurrence or death — and an absolute 24-month DFS improvement of approximately 33 percentage points are among the largest effect sizes reported in adjuvant lung cancer trials, comparable to the ADAURA osimertinib data. The double-blind, placebo-controlled phase III design is methodologically robust. However, several important caveats temper immediate clinical translation: overall survival data remain immature and DFS is a surrogate endpoint; the trial was conducted exclusively in China, limiting generalisability; industry sponsorship by Betta Pharmaceuticals warrants scrutiny; and ensartinib is not TGA-approved or PBS-listed in Australia. The toxicity burden — grade ≥3 adverse events in 35.8% of treated patients — is clinically significant and requires careful patient selection and monitoring. Australian thoracic oncologists should monitor regulatory developments and await OS maturation and head-to-head comparisons with alectinib before incorporating ensartinib into routine adjuvant practice.
Key Findings
P Value: P<0.001 for both primary and key secondary endpoints
Effect Size: Hazard ratio for disease recurrence or death: 0.20 (80% relative risk reduction); absolute DFS difference at 24 months: 32.9 percentage points (stage II–IIIB); overall population: 87.3% vs 57.2% (absolute difference 30.1 percentage points)
Primary Outcome: Disease-free survival in patients with stage II–IIIB ALK-positive NSCLC: 86.4% alive and disease-free at 24 months in the ensartinib group vs 53.5% in the placebo group
Nnt Or Sensitivity: NNT to prevent one recurrence or death at 24 months (stage II–IIIB): approximately 3 (1 ÷ 0.329 absolute risk reduction); Grade ≥3 adverse events: 35.8% ensartinib vs 18.2% placebo (NNH approximately 6)
Confidence Interval: HR 0.20 (95% CI 0.11 to 0.38) for stage II–IIIB population; HR 0.20 (95% CI 0.10 to 0.37) for overall population
Clinical Application
Ensartinib is administered orally at 225 mg once daily, which is logistically feasible in outpatient oncology settings. The 24-month treatment duration requires sustained adherence monitoring. Grade ≥3 toxicity in 35.8% of patients (predominantly rash) necessitates proactive dermatological management and dose modification protocols. ALK testing by validated IHC or FISH/NGS is a prerequisite and is standard of care in Australian thoracic oncology centres. Ensartinib is not currently approved by the Therapeutic Goods Administration (TGA) or listed on the Pharmaceutical Benefits Scheme (PBS) in Australia. The established adjuvant ALK inhibitor in this space internationally is alectinib, which has demonstrated DFS benefit in the ALINA trial (NCT03456076) and has received regulatory attention in multiple jurisdictions. Australian clinicians should note that RACGP and Cancer Australia guidelines recommend ALK testing for all non-squamous NSCLC. If ensartinib seeks TGA registration, comparative efficacy data against alectinib (the current standard of care in the adjuvant ALK-positive setting) will be required. Compassionate access or clinical trial enrolment would be the only current pathways for Australian patients. The predominantly Chinese trial population may limit direct applicability to the Australian demographic. Adults with completely resected, ALK-positive (confirmed by validated diagnostic assay) stage IB to IIIB NSCLC who have completed adjuvant platinum-based chemotherapy and have adequate performance status. The primary benefit was demonstrated in stage II–IIIB disease. Patients with stage IB disease showed benefit in the overall population analysis but this was a secondary endpoint.
Abstract
BACKGROUND: Anaplastic lymphoma kinase (ALK) inhibitors have emerged as promising agents for patients with resectable ALK-positive non-small-cell lung cancer (NSCLC). Whether ensartinib, a second-generation ALK inhibitor, is safe and effective in such patients is unknown. METHODS: In this phase 3, double-blind, randomized trial involving patients with completely resected, ALK-positive stage IB to IIIB NSCLC after adjuvant chemotherapy, we randomly assigned patients in a 1:1 ratio to receive ensartinib at a dose of 225 mg once daily or placebo for 24 months. The primary end point was disease-free survival in patients with stage II to IIIB NSCLC. The key secondary end point was disease-free survival in the overall patient population. RESULTS: A total of 274 patients were randomly assigned to receive ensartinib or placebo (137 patients in each group). At 24 months, the percentage of patients with stage II to IIIB disease who were alive and disease-free was 86.4% in the ensartinib group and 53.5% in the placebo group (hazard ratio for disease recurrence or death, 0.20; 95% confidence interval [CI], 0.11 to 0.38; P<0.001). In the overall patient population, the percentage of patients who were alive and disease-free was 87.3% in the ensartinib group and 57.2% in the placebo group (hazard ratio, 0.20; 95% CI, 0.10 to 0.37; P<0.001). Overall survival data were immature. Adverse events of grade 3 or higher occurred in 35.8% of the patients who received ensartinib (most commonly rash) and in 18.2% of those who received placebo. CONCLUSIONS: Among patients with completely resected stage IB to IIIB ALK-positive NSCLC, the percentage of patients who were alive and disease-free at 24 months was significantly higher with ensartinib than with placebo. (Funded by Betta Pharmaceuticals; ELEVATE ClinicalTrials.gov number, NCT05341583.).
This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service